Efficacy and Safety of Intravenous Immunoglobulin as Adjuvant Treatment for Refractory Neuropathic Pain. Results of an Open-Label, Multicenter Study

Pain Medicine (United States)

Volumn 13, Issue 10, 2012, Pages 1334-1341

  Jann, Stefano ^a   Francia, Ada ^b   Fruguglietti, Maria E ^a   De Toni Franceschini, Luisa ^a   Sterzi, Roberto ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Intravenous immunoglobulin; Neuropathic pain; Peripheral neuropathy; Randomized trial; Refractory pain

Indexed keywords

IMMUNOGLOBULIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; MCGILL PAIN QUESTIONNAIRE; MULTICENTER STUDY; NEUROPATHIC PAIN; OPEN STUDY; OUTPATIENT; PAIN; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POLYNEUROPATHY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; VISUAL ANALOG SCALE;

EID: 84867637641     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01478.x     Document Type: Article

References (33)

1. International Association for the Study of Pain (IASP). Pain terms, a current list with definitions and notes on usage. 2012. Available at: http://www.iasp-pain.org/Content/NavigationMenu/GeneralResourceLinks/PainDefinitions/default.htm (accessed February 16, 2012).
2. Myers RR, Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: Mechanisms and therapeutic targets. Drug Discov Today 2006;11:8-20.
3. Watkins LR, Maier SF. Immune regulation of central nervous system functions: From sickness responses to pathological pain. J Intern Med 2005;257:139-55.
4. Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: Immune cells and molecules. Anesth Analg 2007;105:838-47.
5. Uceyler N, Rogausch JP, Toyka KV, Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology 2007;69:42-9.
6. Doupis J, Lyons TE, Wu S, etal. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009;94:2157-63.
7. Wallace JM. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep 2007;11:208-14.
8. Dworkin RH, O'Connor AB, Backonja M, etal. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-51.
9. Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. N Engl J Med 2003;348:1243-55.
10. Taylor RS. Epidemiology of refractory neuropathic pain. Pain Pract 2006;6:22-6.
11. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, etal. Peripheral neuropathic pain-A multidimensional burden for patients. Eur J Pain 2001;5:379-89.
12. Goebel A, Baranowski A, Maurer K, etal. Intravenous immunoglobulin treatment of the complex regional pain syndrome: A randomized trial. Ann Intern Med 2010;152:152-8.
13. Harel M, Shoenfeld Y. Intravenous immunoglobulin and Guillain-Barre syndrome. Clin Rev Allergy Immunol 2005;29:281-7.
14. Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: Long term follow-up. J Neurol Neurosurg Psychiatry 2009;80:70-3.
15. Morozumi S, Kawagashira Y, Iijima M, etal. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren's syndrome. J Neurol Sci 2009;279:57-61.
16. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008;255(suppl 3):3-6.
17. Jann S, Beretta S, Bramerio M, Defanti CA. Prospective follow-up study of chronic polyneuropathy of undetermined cause. Muscle Nerve 2001;24:1197-201.
18. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990;13:227-36.
19. Commitee for Medicinal Products for Human Use (CHMP). Core SPC for HMAN Normal Immunoglobulin for Intravenous Administration (IVIg) (CPMP/BPWG/859/95 rev. 2). London: European Medicines Agency; April 29, 2004. Available at: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp? (accessed February 16, 2012).
20. Zinman LH, Ngo M, Ng ET, etal. Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: A controlled trial. Diabetes Care 2004;27:921-4.
21. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
22. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: An outcome measure suitable for routine use within the NHS? BMJ 1993;306:1440-4.
23. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 2004;27:26-35.
24. The European Agency for the Evaluation of Medicinal Products (EMEA). Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95). 1995.
25. Caro XJ, Winter EF, Dumas AJ. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology (Oxford) 2008;47:208-11.
26. Goebel A, Netal S, Schedel R, Sprotte G. Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 2002;3:119-27.
27. Goebel A. Immunoglobulin responsive chronic pain. J Clin Immunol 2010;30(suppl 1):S103-8.
28. Engel WK. Intravenous immunoglobulin G is remarkably beneficial in chronic immune dysschwannian/dysneuronal polyneuropathy, diabetes-2 neuropathy, and potentially in severe acute respiratory syndrome. Acta Myol 2003;22:97-103.
29. Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med 2009;10:1476-80.
30. Majani G, Tiengo M, Giardini A, etal. Relationship between MPQ and VAS in 962 patients. A rationale for their use. Minerva Anestesiol 2003;69:67-73.
31. Rigas M, Tandan R, Sterling RJ. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: A retrospective analysis of 1085 infusions. J Clin Neuromuscul Dis 2008;10:52-5.
32. Nadeau JO, Bhibhatbhan A, McDougall D, Toth C. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases. Clin Neurol Neurosurg 2010;112:467-9.
33. Dworkin RH, Turk DC, Peirce-Sandner S, etal. Placebo and treatment group responses in postherpetic neuralgia vs painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 2010;150:12-6.